Monday , January 20 2020
Home / BUSINESS / Suven to participate in 11th clinical trials on Alzheimer’s disease in Spain
Suven to participate in 11th clinical trials on Alzheimer’s disease in Spain

Suven to participate in 11th clinical trials on Alzheimer’s disease in Spain

Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11th clinical trials on Alzheimer’s disease (CTAD) during October 24-27, 2018 at Barcelona, Spain.

SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate Alzheimer’s disease, a novel triple combination treatment approach. This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia.

At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s disease. Top-line efficacy results from this study are expected during August/September of 2019

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.